Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
Quick Look: Six NMEs are up for MHLW panel review on August 26: Ono’s Xcopri, Lundbeck’s Vyepti, Viatris’ Wakix, Alexion’s gefurulimab and anselamimab, and Lilly’s insulin efsitora alfa. The session will also cover Leqembi SC and broader labels for Uplizna…
To read the full story
Related Article
- Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
August 27, 2026
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
- Eisai Files Subcutaneous Leqembi Autoinjector in Japan
December 1, 2025
- Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
- EA Pharma Files to Add Dosage for 1-Year-Olds to Movicol
October 27, 2025
- Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan
October 14, 2025
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
REGULATORY
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
- PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- MHLW Adds Pomalyst Generics to RevMate Safety Program
September 8, 2026
- Japan Extends Shelf Life of Stockpiled Xofluza to 9 Years
September 8, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…